Insulin R/CD220 Antibody (MA-20)

Product Discontinued

Insulin R/CD220 Antibody (MA-20) Summary

• Background: Insulin receptor plays a major part in the regulation of glucose homeostasis, which when malfunctioning can result in diabetes and cancer. Encoded by the INSR gene, insulin receptor has two isoforms produced by alternative splicing, HIR-B and HIR-A.
• Immunogen: Highly purified Insulin Receptor (alpha-subunit) from human term placentas. [UniProt# P06213]
• Localization: Membrane; single pass type I membrane protein.
• Isotype: IgG2b
• Clonality: Monoclonal
• Host: Mouse
• Gene: INSR
• Purity: Protein G purified

Applications/Dilutions

• Dilutions:
  • Block/Neutralize
  • ELISA 1:100-1:2000
  • Immunoprecipitation 1:10-1:500
  • Western Blot 1:100-1:2000
• Application Notes: This Insulin Receptor (MA-20) antibody is useful for ELISA, Immunoprecipitation, Western blot and Blocking/Neutralizing assays.

Reactivity Notes

Human and rat. Mouse reactivity reported in scientific literature (PMID: 24389353)

Packaging, Storage & Formulations

• Storage: Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.
• Buffer: 10mM Phosphate (pH 7.4) and 0.1M NaCl
• Preservative: 0.1% Sodium Azide
• Concentration: 1.2 mg/ml
• Purity: Protein G purified

Alternate Names for Insulin R/CD220 Antibody (MA-20)

• CD 220
• CD220 antigen
• CD220
• EC 2.7.10
• EC 2.7.10.1
• HHF5
• INSR
• Insulin R
• insulin receptor
• InsulinR
• IR

Background

Insulin receptor plays a major part in the regulation of glucose homeostasis, which when malfunctioning can result in diabetes and cancer. Encoded by the INSR gene, insulin receptor has two isoforms produced by alternative splicing, HIR-B and HIR-A.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Insulin R/CD220 Antibody (NB400-142)(17)

Publications using NB400-142

• Tumminia A, Scalisi NM, Milluzzo A et al. Maternal Diabetes Impairs Insulin and IGF-1 Receptor Expression and Signaling in Human Placenta Frontiers in endocrinology 2021-03-10 [PMID: 33776919]
• Youssef A, K M Han V. Low Oxygen Tension Modulates the Insulin-like Growth Factor -1 or -2 Signaling via Both Insulin-like Growth Factor-1 Receptor and Insulin Receptor to Maintain Stem Cell Identity in Placental Mesenchymal Stem Cells. Endocrinology. 2016-01-13 [PMID: 26760116] (WB, Human)
• Kippenberger S, Zoller N, Kleemann J et al. STAT6-Dependent Collagen Synthesis in Human Fibroblasts Is Induced by Bovine Milk PLoS ONE. 2015-07-03 [PMID: 26134630] (B/N, Human)
• Morcavallo A, Buraschi S, Xu SQ et al. Decorin differentially modulates the activity of insulin receptor isoform A ligands. Matrix Biol 2014-01-02 [PMID: 24389353] (ELISA, Mouse)
• Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R, Belfiore A. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem;277(42):39684-95. 2002-10-18 [PMID: 12138094] (IP, WB, ELISA, Human)
• Vella V, Pandini G, Sciacca L, Mineo R, Vigneri R, Pezzino V, Belfiore A. A novel autocrine loop involving IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J Clin Endocrinol Metab;87(1):245-54. 2002-01-01 [PMID: 11788654]
• Li, M et al. Small molecule insulin receptor activators potentiate insulin action in insulin-resistant cells. Diabetes;50(10):2323-8. 2001-10-01 [PMID: 11574415] (ELISA, WB, Human)
• Costanzo BV, Trischitta V, Di Paola R, Spampinato D, Pizzuti A, Vigneri R, Frittitta L. The Q allele variant (GLN121) of membrane glycoprotein PC-1 interacts with the insulin receptor and inhibits insulin signaling more effectively than the common K allele variant (LYS121). Diabetes;50(4):831-6. 2001-04-01 [PMID: 11289049] (ELISA, Human)
• Maddux BA, Goldfine ID. Membrane glycoprotein PC-1 inhibition of insulin receptor function occurs via direct interaction with the receptor alpha-subunit. Diabetes;49(1):13-9. 2000-01-01 [PMID: 10615944]
• Pandini G, Vigneri R, Costantino A, Frasca F, Ippolito A, Fujita-Yamaguchi Y, Siddle K, Goldfine ID, Belfiore A. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res;5(7):1935-44. 1999-07-01 [PMID: 10430101]
• Frasca, F et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol;19(5):3278-88. 1999-05-01 [PMID: 10207053] (IP, ELISA, Human)
• Federici, M et al. Increased expression of insulin/insulin-like growth factor-I hybrid receptors in skeletal muscle of noninsulin-dependent diabetes mellitus subjects. J Clin Invest;98(12):2887-93. 1996-12-15 [PMID: 8981937] (WB, Human)
• Gherzi R, Russell DS, Taylor SI, Rosen OM. Reevaluation of the evidence that an antibody to the insulin receptor is insulinmimetic without activating the protein tyrosine kinase activity of the receptor. J Biol Chem;262(35):16900-5. 1987-12-15 [PMID: 3680277]
• Forsayeth JR, Caro JF, Sinha MK, Maddux BA, Goldfine ID. Monoclonal antibodies to the human insulin receptor that activate glucose transport but not insulin receptor kinase activity. Proc Natl Acad Sci U S A;84(10):3448-51. 1987-05-01 [PMID: 3033648] (B/N, IP, Human)
• Hawley DM, Maddux BA, Patel RG, Wong KY, Mamula PW, Firestone GL, Brunetti A, Verspohl E, Goldfine ID. Insulin receptor monoclonal antibodies that mimic insulin action without activating tyrosine kinase. J Biol Chem;264(5):2438-44. 1989-02-15 [PMID: 2536710]
• Forsayeth, JR et al. Effect of monoclonal antibodies on human insulin receptor autophosphorylation, negative cooperativity, and down-regulation. J Biol Chem;262(9):4134-40. 1987-03-25 [PMID: 2435731] (B/N, Human)
• Milazzo G, Giorgino F, Damante G, Sung C, Stampfer MR, Vigneri R, Goldfine ID, Belfiore A. Insulin receptor expression and function in human breast cancer cell lines. Cancer Res;52(14):3924-30. 1992-07-15 [PMID: 1617668]

FAQs for Insulin R/CD220 Antibody (NB400-142). (Showing 1 - 3 of 3 FAQs).

1. Our customer would like to perform IHC with samples from Rat. She has questions regarding antibodies of choice: 1. Is it possible to use NB400-142 for IHC? 2. I am having difficulty of choosing between NBP1-77679 and NBP1-77680. Would you please help suggest? 3. Although it is described as IHC (-) on the product page of NBP1-07034, This antibody did not work in IHC with mouse tissue is also described. How about Rat samples? Is it possible that the antibody can work in IHC with rat tissues?
   • To answer your questions about NB400-142, this antibody has not been validated for IHC and we cannot guarantee that it will work. Both NBP1-77679 and NBP1-77680 have been validated for use in rat and IHC. The difference between these 2 antibodies is the immunogen as they were raised against different regions of the protein. Please point out the immunogen to your customer and have them decide what would be best for their research. NBP1-07034 does not work in IHC, it is only guaranteed for Western blot in human, mouse and rat. When an application is followed by a (-) I would not recommend using this application in any species.
2. I am currently looking for an antibody that specifically blocks the insulin receptor (IR) without activation. You have a number of anti-IR antibodies that are categorized as blocking antibodies. However, looking through the relevant publications, I am unable to determine 1) if they induce any activation or 2) if they also react with IGR-1r. So I have two questions: Do any of your antibodies block the IR without activating it? Do any of your antibodies block the IR without interfering with IGF-1r activity? What is the molar concentration of MA-20 is NB400-142? The only concentration on the data sheet is in mg/ml and there is no listed molecular weight.
   • NB400-142 is our only Insulin Receptor antibody with blocking activity. As you can see in the background information for this antibody: The insulin receptor is functionally important for negative cooperatively, down-regulation, and beta-subunit tyrosine kinase activity. There are two recognized epitopes of the alpha-subunit. One epitope is close to the insulin-binding site and plays a role in insulin-induced negative cooperatively and down-regulation. The other site (recognized by the monoclonal MA-20 antibody) is at a distance from the insulin-binding site, where it only plays a role in down-regulation. Both epitopes appear to be independent of insulin receptor tyrosine kinase activity. MA-20 is NB400-142. We have no information about its interactions with IGF-1r.This antibody is an IgG2b. The molecular weight is around 150 kDa, as are all IgG antibodies. We do not determine the exact weight of our antibodies.
3. I am looking for an antibody which will detect only the full length isoform Insulin receptor beta and no cross reactivity with the alpha. Is your antibody only detecting the beta form? Did you test for cross-reactivity with the alpha form? I believe that the insulin receptor beta (generated by exon 11 inclusion), is characterized by the presence of 12 aa at the C-terminus of the alpha-subunit, which is why I think the antibody might cross react.
   • NB400-142 recognizes the alpha subunit. NBP2-16970, NBP2-12793, NBP1-19192 and NBP2-12793 are all directed at the beta subunit. None of these should cross-react with the alpha subunit as they share no sequence similarity.

Bioinformatics

• Gene Symbol: INSR